Starpharma Holdings Limited (ASX:SPL – Get Free Report) insider Robert Thomas acquired 300,000 shares of Starpharma stock in a transaction that occurred on Tuesday, November 5th. The stock was acquired at an average cost of A$0.09 ($0.06) per share, with a total value of A$27,900.00 ($18,476.82).
Robert Thomas also recently made the following trade(s):
- On Wednesday, October 23rd, Robert Thomas acquired 200,000 shares of Starpharma stock. The stock was acquired at an average cost of A$0.09 ($0.06) per share, with a total value of A$18,600.00 ($12,317.88).
Starpharma Stock Performance
The company has a debt-to-equity ratio of 12.55, a current ratio of 4.94 and a quick ratio of 5.65.
About Starpharma
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom.
Further Reading
- Five stocks we like better than Starpharma
- How Can Investors Benefit From After-Hours Trading
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- Why Invest in 5G? How to Invest in 5G Stocks
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Why Are These Companies Considered Blue Chips?
- MarketBeat Week in Review – 11/4 – 11/8
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
